MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
36.35
-2.72 (-6.96%)
At close: Apr 1, 2025, 4:00 PM
37.75
+1.40 (3.84%)
After-hours: Apr 1, 2025, 4:53 PM EDT
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,189,355
Market Cap
2.30B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MLTX News
- 4 weeks ago - MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
- 2 months ago - MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - GlobeNewsWire
- 7 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire
- 9 months ago - MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward - Seeking Alpha
- 11 months ago - MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa - GlobeNewsWire
- 11 months ago - MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion - Seeking Alpha
- 11 months ago - MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire